Comparative Pharmacology
Head-to-head clinical analysis: MYCITRACIN versus PEDIAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCITRACIN versus PEDIAZOLE.
MYCITRACIN vs PEDIAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MYCITRACIN is a combination of bacitracin and neomycin, which are aminoglycoside antibiotics. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan subunits. Neomycin binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Pediazole is a combination of erythromycin (a macrolide antibiotic that binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis) and sulfisoxazole (a sulfonamide that inhibits dihydropteroate synthase, blocking folic acid synthesis).
500 mg orally every 6 hours
Adults: 1 mg/kg intravenously every 6 hours.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours in adults with normal renal function. Prolonged significantly in renal impairment (up to 24–48 hours in anuria).
Terminal half-life is approximately 6-8 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment.
Primarily renal (glomerular filtration and tubular secretion); >90% of dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<5%).
Renal excretion of unchanged drug accounts for approximately 70-80% of the dose; biliary/fecal elimination is minor (<10%).
Category C
Category C
Antibiotic Combination
Antibiotic Combination